Inaugural Evidence-Based Reimbursement Summit to be held November 5-7 in Philadelphia, PA

Cambridge Healthtech Institute's inaugural Evidence-Based Reimbursement Summit is being held November 5-7, 2012 in Philadelphia, PA. Will feature Generating Evidence for Reimbursement Decisions: Therapeutics and Diagnostics.
Spread the Word
Listed Under

CPT Code Change


Needham - Massachusetts - US


Sept. 20, 2012 - PRLog -- The Evidence-Based Reimbursement Summit will take place November 5-7 at the Hyatt Regency Philadelphia at Penn's Landing, and is comprised of two conferences divided into two parts. Part I - Generating Evidence for Reimbursement Decisions: Therapeutics is designed to bring together all major stakeholders in the field of evidence-based reimbursement, clinical development experts, reimbursement and government affairs specialists, health care economists and payers. Part II - Generating Evidence for Reimbursement Decisions: Diagnostics is designed to encourage knowledge exchange among major players the field of evidence-based reimbursement in diagnostics.

There will be a bridging session between Part I and Part II entitled Evidence-Based Reimbursement in Personalized Medicine / Companion Diagnostics. This session provides a unique opportunity for professionals working in the area of drug-diagnostics co-development to learn more about challenges and solutions in the critically important area of reimbursement that their partners face on the daily basis.

The complete conference agendas can be found at

Distinguished Faculty Includes:

Allan Korn, M.D., CMO & Senior Vice President, Clinical Affairs, Blue Cross and Blue Shield Association
Amy Guo, Ph.D., Head US HEOR, Novartis Oncology
Badri Rengarajan, M.D., Medical Director, Archimedes, Inc.
Danielle Scelfo, Associate Director, Government Affairs, Genomic Health
David Recker, M.D., Vice President, Clinical Development, Takeda
Douglas J. Moeller M.D., Medical Director, Claims Performance & Advanced Diagnostics Management, McKesson Health Solutions
Elise Berliner, Ph.D., Director, Technology Assessment Program, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality
Ester Stein, MBA, Director, Corporate Reimbursement and Government Affairs, Abbott Molecular
Jeffrey A. Kant, M.D., Ph.D., FCAP, Director, Division of Molecular Diagnostics, University of Pittsburgh Medical Center Health System
Jerry Conway, Vice President, Reimbursement and Payer Strategy, Foundation Medicine, Inc.
Joshua Cohen, Ph.D., Senior Research Fellow & Assistant Professor, Tufts Center for the Study of Drug Development
Karl Florence, Director of Reimbursement, Vermillion
Larry Z. Liu, M.D., Ph.D., Senior Director, Global Health Economics & Outcomes Research Market Access, Pfizer Primary Care BU
Laura Housman, MPH, MBA, Vice President, Global Market Access, Pricing and HE&OR, Novartis Molecular Diagnostics
Laura Sullivan, Vice President, Customer Care & Reimbursement, Good Start Genetics
Louis Fiore, M.D., Executive Director, Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Department of Veterans Affairs
Marcus Wilson, Pharm.D., President, HealthCore, Inc.
Matthew Zubiller, Vice President, Decision Management at McKesson Corporation
Robert Popovian, Pharm.D., MS, Senior Director, Advocacy and Professional Relations, US Public Affairs, Pfizer, Inc.
Sheikh Usman Iqbal, M.D., MPH, MBA, Senior Director & Head, Oncology, Global Evidence & Value Development (EVD), Medical Affairs, Global R+D, Sanofi
Tim Wright, Director of Global Payer Research and Strategy

There is an advance registration discount of $200 offered until Friday, September 21.  Registration information is available at
Email:*** Email Verified
Tags:Reimbursement, CPT Code Change, Diagnostics, Therapetuics
Industry:Medical, Biotech
Location:Needham - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Cambridge Healthtech Institute PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share